It takes money to make money. Most investors know that, but with business media so focused on the "how much," very few investors bother to ask, "How fast?"
When judging a company's prospects, how quickly it makes real cash money can be just as important as how much it's currently generating in the accounting fantasy world we call "earnings." It's one of the first metrics I check when I'm hunting for the market's best stocks. Today, we'll see how it applies to Eli Lilly (NYSE: LLY).
Let's break this down
In this series, we measure how swiftly a company turns cash into goods or services and back into cash. We'll use a quick, relatively foolproof metric known as the cash conversion cycle, or CCC for short.
Why does the CCC matter? The less time it takes a firm to convert outgoing cash into incoming cash, the more powerful and flexible its profit engine is. The less money tied up in inventory and accounts receivable, the more available to grow the company, pay investors, or both.
To calculate the cash conversion cycle, add days inventory outstanding to days sales outstanding, then subtract days payable outstanding. Like golf, the lower your score here, the better.
Here's the CCC for Eli Lilly alongside the comparable figures from a few competitors and peers.
|
Company |
TTM Revenue |
TTM CCC |
|---|---|---|
| Eli Lilly | $23,430 | 187 |
| Abbott Laboratories (NYSE: ABT) | $36,509 | 112 |
| Teva (Nasdaq: TEVA) | $16,548 | 196 |
| Pfizer (NYSE: PFE) | $67,735 | 204 |
Source: Capital IQ, a division of Standard & Poor's. Dollar amounts in millions. Data is current as of last fully reported fiscal quarter. TTM = trailing 12 months.
For younger, fast-growth companies, the CCC can give you valuable insight into the sustainability of that growth. A company that's taking longer to make cash may need to tap financing to keep its momentum. For older, mature companies, the CCC can tell you how well the company is managed. Firms that begin to lose control of the CCC may be losing their clout with their suppliers (who might be demanding stricter payment terms) and customers (who might be demanding more generous terms). This can sometimes be an important signal of future distress -- one most investors are likely to miss.
While I find peer comparisons useful, I'm most interested in comparing a company's CCC to its prior performance. Here's where I believe all investors need to become trend-watchers. Sure, there may be legitimate reasons for an increase in the CCC, but all things being equal, I want to see this number stay steady or move downward over time.
Source: Capital IQ, a division of Standard & Poor's. Dollar amounts in millions. FY = fiscal year. TTM = trailing 12 months.
Because of the seasonality in some businesses, the CCC for the TTM period may not be strictly comparable to the fiscal-year periods shown in the chart. Even the steadiest-looking businesses on an annual basis will experience some quarterly fluctuations in the CCC. To get an understanding of the usual ebb and flow at Eli Lilly consult the quarterly period chart below.
Source: Capital IQ, a division of Standard & Poor's. Dollar amounts in millions. FQ = fiscal quarter.
On a 12-month basis, the trend at Eli Lilly looks good. At 186.7 days, it is 4.7 days better than the five-year average of 191.4 days. The biggest contributor to that improvement was DPO, which decreased 6.0 days compared to the five-year average. That was partially offset by a 2.3-day increase in DSO.
Considering the numbers on a quarterly basis, the CCC trend at Eli Lilly looks good. At 185.9 days, it is little changed from the average of the past eight quarters. With both 12-month and quarterly CCC running better than average, Eli Lilly gets high marks in this cash-conversion checkup.
Though the CCC can take a little work to calculate, it's definitely worth watching every quarter. You'll be better informed about potential problems, and you'll improve your odds of finding the underappreciated home run stocks that provide the market's best returns.
To stay on top of the CCC for your favorite companies, just use the handy links below to add companies to your free watchlist.
- Add Eli Lilly to My Watchlist.
- Add Abbott Laboratories to My Watchlist.
- Add Teva to My Watchlist.
- Add Pfizer to My Watchlist.
